GlassScriptPhysician profile
Timothy R Oneill
NPI 1033117890
$6,047.57
in general payments reported to CMS, 2019-2025
54 companies · $996 in 2025
The $996 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $244 · 2021: $992 · 2022: $1,370 · 2023: $1,180 · 2024: $922 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,010.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $961.10 | 2020-2025 | |
| Amgen INC. | $501.37 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Lilly USA, LLC | $475.17 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $450.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $334.21 | 2020-2025 | Gardasil 9, Verquvo, Vaxneuvance |
| Astellas Pharma US INC | $270.48 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $230.07 | 2022-2025 | |
| Corium, LLC | $168.83 | 2022-2024 | Azstarys |
| Novartis Pharmaceuticals Corporation | $148.96 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $122.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $105.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $91.57 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $88.29 | 2022-2025 | Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $77.80 | 2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Oneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.